These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37145959)

  • 1. Propensities of Fatty Acid-Modified ASOs: Self-Assembly vs Albumin Binding.
    Kusznir EA; Hau JC; Portmann M; Reinhart AG; Falivene F; Bastien J; Worm J; Ross A; Lauer M; Ringler P; Sladojevich F; Huber S; Bleicher K; Keller M
    Bioconjug Chem; 2023 May; 34(5):866-879. PubMed ID: 37145959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation.
    Hvam ML; Cai Y; Dagnæs-Hansen F; Nielsen JS; Wengel J; Kjems J; Howard KA
    Mol Ther; 2017 Jul; 25(7):1710-1717. PubMed ID: 28641935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle.
    Prakash TP; Mullick AE; Lee RG; Yu J; Yeh ST; Low A; Chappell AE; Østergaard ME; Murray S; Gaus HJ; Swayze EE; Seth PP
    Nucleic Acids Res; 2019 Jul; 47(12):6029-6044. PubMed ID: 31127296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Albumin-Binding Fatty Acid-Modified Gapmer Antisense Oligonucleotides for Modulation of Pharmacokinetics.
    Cai Y; Lou C; Wengel J; Howard KA
    Methods Mol Biol; 2020; 2176():163-174. PubMed ID: 32865790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity.
    Liang XH; Shen W; Sun H; Kinberger GA; Prakash TP; Nichols JG; Crooke ST
    Nucleic Acids Res; 2016 May; 44(8):3892-907. PubMed ID: 26945041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the Knockdown Activity of MALAT1 ENA Gapmers In Vitro.
    Iwashita S; Shoji T; Koizumi M
    Methods Mol Biol; 2020; 2176():155-161. PubMed ID: 32865789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The intratracheal administration of locked nucleic acid containing antisense oligonucleotides induced gene silencing and an immune-stimulatory effect in the murine lung.
    Uemura Y; Hagiwara K; Kobayashi K
    PLoS One; 2017; 12(11):e0187286. PubMed ID: 29107995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of multivalent fatty acid-conjugated antisense oligonucleotides: Cell internalization, physical properties, and in vitro and in vivo activities.
    Tanaka Y; Tanioku Y; Nakayama T; Aso K; Yamaguchi T; Kamada H; Obika S
    Bioorg Med Chem; 2023 Mar; 81():117192. PubMed ID: 36780806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mouse genome-wide association studies and systems genetics uncover the genetic architecture associated with hepatic pharmacokinetic and pharmacodynamic properties of a constrained ethyl antisense oligonucleotide targeting Malat1.
    Pirie E; Ray S; Pan C; Fu W; Powers AF; Polikoff D; Miller CM; Kudrna KM; Harris EN; Lusis AJ; Crooke RM; Lee RG
    PLoS Genet; 2018 Oct; 14(10):e1007732. PubMed ID: 30372444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the Prion Protein Binding Properties of Antisense Oligonucleotides.
    Reidenbach AG; Minikel EV; Zhao HT; Guzman SG; Leed AJ; Mesleh MF; Kordasiewicz HB; Schreiber SL; Vallabh SM
    Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31861275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered Biodistribution and Hepatic Safety Profile of a Gapmer Antisense Oligonucleotide Bearing Guanidine-Bridged Nucleic Acids.
    Sasaki T; Hirakawa Y; Yamairi F; Kurita T; Murahashi K; Nishimura H; Iwazaki N; Yasuhara H; Tateoka T; Ohta T; Obika S; Kotera J
    Nucleic Acid Ther; 2022 Jun; 32(3):177-184. PubMed ID: 35073217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice.
    Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioanalysis of free antisense oligonucleotide payload from antibody-oligonucleotide conjugate by hybridization LC-MS/MS.
    Jiang D; Li P; Yuan L
    Bioanalysis; 2024; 16(15):791-800. PubMed ID: 39041663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surface Plasmon Resonance Assay of Binding Properties of Antisense Oligonucleotides to Serum Albumins and Lipoproteins.
    Onishi R; Watanabe A; Nakajima M; Sekiguchi M; Kugimiya A; Kinouchi H; Nihashi Y; Kamimori H
    Anal Sci; 2015; 31(12):1255-60. PubMed ID: 26656814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid Conjugates Enhance Endosomal Release of Antisense Oligonucleotides Into Cells.
    Wang S; Allen N; Prakash TP; Liang XH; Crooke ST
    Nucleic Acid Ther; 2019 Oct; 29(5):245-255. PubMed ID: 31158063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Locked Nucleic Acid Gapmers and Conjugates Potently Silence ADAM33, an Asthma-Associated Metalloprotease with Nuclear-Localized mRNA.
    Pendergraff HM; Krishnamurthy PM; Debacker AJ; Moazami MP; Sharma VK; Niitsoo L; Yu Y; Tan YN; Haitchi HM; Watts JK
    Mol Ther Nucleic Acids; 2017 Sep; 8():158-168. PubMed ID: 28918018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phospholamban Inhibition by a Single Dose of Locked Nucleic Acid Antisense Oligonucleotide Improves Cardiac Contractility in Pressure Overload-Induced Systolic Dysfunction in Mice.
    Morihara H; Yamamoto T; Oiwa H; Tonegawa K; Tsuchiyama D; Kawakatsu I; Obana M; Maeda M; Mohri T; Obika S; Fujio Y; Nakayama H
    J Cardiovasc Pharmacol Ther; 2017 May; 22(3):273-282. PubMed ID: 27811197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interplay between copper(II), human serum albumin, fatty acids, and carbonylating agent interferes with Cys 34 thiol reactivity and copper binding.
    Penezić AZ; Aćimović JM; Pavićević ID; Jovanović VB; Takić M; Mandić LM
    J Biol Inorg Chem; 2019 Feb; 24(1):61-70. PubMed ID: 30456476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
    Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
    J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carrier-protein-mediated enhancement of fatty-acid binding and internalization in human T-lymphocytes.
    Uriel J; Torres JM; Anel A
    Biochim Biophys Acta; 1994 Feb; 1220(3):231-40. PubMed ID: 7508265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.